CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 125 enrolled
Drug / intervention
Rhodiola crenulata +1 moredrug
Likely dose
Rhodiola crenulata 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01536288
NCT01536288Phase 2Completed

Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness.

Chang Gung Memorial Hospital·interventional·Posted Feb 22, 2012·Updated Feb 22, 2012

In Brief

A Phase 2 clinical trial evaluating Rhodiola crenulata and placebo for Acute Mountain Sickness and Environmental Illness. Completed, enrolled 125 participants across 1 site.

Detailed Summary

Traditional folk medicine in the Arctic and Himalayan areas used Rhodiola species to enhance physical endurance, prevent aging, resist acute mountain sickness (AMS), and to treat fatigue, depression, anemia, impotence and respiratory infections. Rhodiola crenulata are widely used to prevent AMS in Himalayan areas and Lhasa in Tibet but none was examined by human study. The investigators conducted a randomized, double blind, placebo controlled, crossover study to investigate the efficacy of Rhodiola crenulata in preventing AMS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2012
Enrollment StartOct 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.4 years ago

Interventions

Rhodiola crenulatadrug

Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering

placebodrug

Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering